Keratoconus, often referred to as “KC”, is a non-inflammatory eye condition in which the typically round dome-shaped cornea progressively thins and weakens, causing the development of a cone-like bulge and optical irregularity of the cornea. This causes “static” in your vision and can result in significant vision impairment.
Corneal Cross-Linking: Patient FAQs
Cross-linking is a minimally invasive, FDA approved, outpatient procedure that combines the use of riboflavin eye drops, Photrexa® Viscous, (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), and ultra-violet A (UVA) light from the KXL® system for the treatment of progressive keratoconus.
Riboflavin (vitamin B2) is naturally occurring in the body, including the eye. It is a photosensitizer. Riboflavin is non-toxic and is used as an additive in food and pharmaceuticals.
UVA is one of the three types of invisible light rays given off by the sun (together with ultra- violet B and ultra-violet C) and is the weakest of the three.
Yes, your doctor will apply topical anesthesia to numb the eye prior to the removal of the epithelium. This process helps to prepare your eye so that the drug can penetrate the tissue of the cornea to have an effective cross-linking procedure.
Yes, typically you will be awake during the treatment. You’ll be given relaxing medication and numbing anesthetic drops.
The actual procedure takes about an hour, but you will be at the office for approximately two hours to allow sufficient time for preparation and recovery before you return to the comfort of your own home.
- After numbing drops are applied, the epithelium (the thin layer on the surface of the cornea) is gently removed.
- Photrexa Viscous eye drops will be applied to the cornea for at least 30 min;
- Depending on the thickness of your cornea, Photrexa drops may also be required.
- The cornea is then exposed to UV light for 30 minutes while additional Photrexa Viscous drops are applied.
- You should not rub your eyes for the first five days after the procedure.
- You may notice a sensitivity to light and have a foreign body sensation. You may also experience discomfort in the treated eye and sunglasses may help with light sensitivity.
- If you experience severe pain in the eye or any sudden decrease in vision, you should contact your physician immediately.
- If your bandage contact lens from the day of treatment falls out or becomes dislodged, you should not replace it and contact your physician immediately.
There is some discomfort during immediate recovery but usually not during the treatment. Immediately following treatment, a bandage contact lens is placed on the surface of the eye to protect the newly treated area. After the numbing drops wear off, there is some discomfort, often described as a gritty, burning sensation managed with Tylenol and artificial tears. If pain is severe, oral narcotic medications may be used.
No. There is no change in the appearance of your eyes following cross-linking.
Patients over the age of 14 who have been diagnosed with progressive keratoconus should ask their doctor whether they may be an appropriate candidate for corneal cross-linking.
Yes. Typically, doctors ask their patients to stop wearing contact lenses prior to surgery for a period of up to several weeks. Once treated, patients may not be allowed back into contact lenses for 1 month.
Please contact your doctor for specific pricing information. To find a physician in your area who is performing the FDA-Approved procedure, you can search the Physician Locator: http://www.livingwithkeratoconus.com/find-an-expert/.
In two clinical trials, progressive keratoconus patients treated with corneal cross-linking had an average Kmax1 reduction (which is flattening) of 1.4 diopters in Study 1 and 1.7 diopters in Study 2 at 12-months post-procedure, while untreated patients had an average increase (which is steepening) of 0.5 diopters in Study 1 and 0.6 diopters in Study 2 at 12-months post-procedure. Individual results may vary.
1. Kmax is the measurement of the maximum corneal curvature.
Summary of Information About Corneal Cross-Linking
What is corneal cross-linking?
- Corneal cross-linking is a minimally invasive outpatient procedure that combines the use of Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and the KXL® system for the treatment of progressive keratoconus.
What warnings should I know about cross-linking?
- Ulcerative keratitis, a potentially serious eye infection, can occur.
- Your doctor should monitor your resolution of epithelial defects if they occur.
What are the side effects of corneal cross-linking?
- The most common ocular adverse reactions in any corneal cross-linked eye were haze (corneal opacity), inflammation (punctate keratitis), fine white lines (corneal striae), disruption of surface cells (corneal epithelium defect), eye pain, reduced sharpness of vision (visual acuity) and blurred vision.
The safety and effectiveness of corneal cross-linking has not been established in pregnant women, women who are breastfeeding, patients who are less than 14 years of age and patients 65 years of age or older. The risk information provided here is not comprehensive. To learn more, talk about corneal cross-linking with your healthcare provider. The FDA-approved product labeling can be found at Avedro.com. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1.800.FDA.1088.